Convergent Therapeutics

MA - CambridgeBiotechnology2 H-1B visas (FY2023)

Focus: Convergent Therapeutics is a 2024-founded Cambridge biotech specializing in radiotherapies for oncology and respiratory indications. The company is in pre-clinical/early-stage development with a nascent pipeline.

Oncology Respiratory

Profile data last refreshed 2d ago · AI intelligence enriched 2w ago

Open Jobs

About Convergent Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Convergent Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

7 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

RT Assistant

Respiratory Therapy

N/A

Clinical Trials (1)

NCT05661695Evaluation of Clinical Tool to Improve Adherence to Ventilator Management at UM

N/A

Help build intelligence for Convergent Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Ground-floor opportunity at a newly founded company (2024) with potential to shape culture and early strategy
Focus on radiotherapy is a differentiated modality with less saturated talent competition than traditional small molecule or antibody spaces
Early-stage oncology + respiratory pipeline positions company at intersection of high-unmet-need markets

Watch Out For

Zero active job postings and minimal public hiring signals suggest company is still in stealth/pre-scaling mode with limited near-term hiring
Pre-revenue status with no disclosed funding means significant execution and financing risk; early employees face dilution and burn-rate uncertainty
Only 2 clinical-stage programs (Phase 1–2) and heavily diversified pipeline (devices, diagnostics, COVID preservation media) suggest unfocused strategy and diluted resource allocation

Generated by Claude from Convergent Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Oro-nasal Mask

Noninvasive Ventilation

N/A

Clinical Trials (1)

NCT02383719A Feasibility Study Evaluating the Use of a Non-invasive Ventilation Mask

N/A

Electrode-based Sensor for Non-invasive Fetal Heart Rate and EMG Monitoring With Improved Reliabilit

Pregnancy

N/A

Clinical Trials (1)

NCT01400880Electrode-based Sensor for Non-invasive Fetal Heart Rate and EMG Monitoring With Improved Reliability

Phase 1

Enhanced Preservation Media

SARS-CoV-2

N/A

Clinical Trials (1)

NCT05281692Comparison of EPM-IX to Currently Used Specimen Transportation and Extraction Devices ( CGI-EPM-IX )

N/A

RT Assistant

Respiratory Therapy

N/A

Clinical Trials (1)

NCT05626699Evaluation of Clinical Tool to Improve Adherence to Ventilator Management

N/A

Actinium-J591

Prostate Cancer Metastatic

Phase 1

Clinical Trials (1)

NCT05567770ACTInium-J591 Radionuclide Therapy in PSMA-Detected Metastatic HOrmone-Sensitive Recurrent Prostate CaNcer

Phase 1

In-111 rosopatamab tetraxetan

PSMA PET-Positive Castration-Resistant Prostate Cancer

Phase 2

Clinical Trials (1)

NCT06549465Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)

Phase 2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2024

Portfolio: 7 clinical trials

Top TAs: Respiratory, Oncology

H-1B (2023): 2 approvals

Therapeutic Area Focus

Respiratory

3 pipeline

Oncology

2 pipeline

Marketed

Pipeline

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo